$SNEX

Maurer Mark Lowry sold $1.3M of SNEX

Maurer Mark Lowry sold 11,398 shares of StoneX Group Inc. (SNEX) at $112.25 ($1.28M total) on 2026-05-22.

Original reporting
SEC EDGAR · Maurer Mark Lowry
Published May 26, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
medium confidence
Mentioned
$SNEX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralMed
01

Why it matters

The market may briefly reassess sentiment around SNEX due to insider selling, but absent any operational catalyst, the effect is likely modest and short-lived.

02

Market read

A disclosed insider sale can influence near-term sentiment, but the filing alone does not provide new fundamentals.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article lacks context on tax, diversification, or other personal constraints that often drive Form 4 sales.

Relevance 7/10Timing: Immediate (new SEC Form 4 disclosure dated 2026-05-26 for a sale on 2026-05-22).

Background

This is an SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralMedium confidence
Context

StoneX Group insider Maurer Mark Lowry sold 11,398 shares in an open-market transaction worth about $1.28M, disclosed via SEC Form 4.

Expected impact

Likely limited, short-lived negative bias to sentiment; any move should fade unless accompanied by other company-specific news.

Evidence & confidence

Single insider sale size is disclosed, but the article provides no earnings/guidance, deal, or regulatory developments—so impact is primarily sentiment/positioning rather than fundamentals.

Market effects

Minimal; insider transaction filings rarely change sector fundamentals without accompanying operational/regulatory developments.

Minimal; StoneX is US-listed and the event is company-specific insider activity.

Minimal; no cross-border deal, regulation, or macro shock is referenced.

Counterpoint

Insider sales can be routine liquidity/portfolio rebalancing and may not signal reduced business confidence, especially when holdings remain substantial.

Key entities

  • StoneX Group Inc.

    Subject of the insider transaction disclosure; Maurer Mark Lowry sold shares via open-market sale.

  • Maurer Mark Lowry

    Reporter of the Form 4; sold 11,398 shares at $112.2455 on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.